BRIEF-Incyte Announces Positive Topline Results From Study Of Tafasitamab

Reuters01-05

Jan 5 (Reuters) - Incyte Corp INCY.O:

INCYTE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL STUDY OF TAFASITAMAB (MONJUVI®/MINJUVI®) AS A FIRST-LINE TREATMENT FOR DIFFUSE LARGE B-CELL LYMPHOMA
INCYTE - PHASE 3 FRONTMIND TRIAL MEETS PRIMARY ENDPOINT OF PFS
INCYTE - PLANS TO FILE SBLA FOR TAFASITAMAB IN 2026
INCYTE - TRIAL MEETS SECONDARY ENDPOINT OF EVENT-FREE SURVIVAL
INCYTE: EXPECTS TO FILE A SBLA FOR TAFASITAMAB FOR FIRST-LINE TREATMENT OF ADULTS WITH NEWLY DIAGNOSED DLBCL IN H1 2026

Source text: ID:nBw35KXBqa

Further company coverage: INCY.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601882274?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-05 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601882274","market":"fut","top_or_hot":-1,"title":"BRIEF-Incyte Announces Positive Topline Results From Study Of Tafasitamab","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Incyte Announces Positive Topline Results From Study Of Tafasitamab </title></head><body><p><span>Jan 5 (Reuters)</span><span> - </span>Incyte Corp <span>INCY.O</span>:</p><ul><li><p>INCYTE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL STUDY OF TAFASITAMAB (MONJUVI®/MINJUVI®) AS A FIRST-LINE TREATMENT FOR DIFFUSE LARGE B-CELL LYMPHOMA</p></li><li><p>INCYTE - PHASE 3 FRONTMIND TRIAL MEETS PRIMARY ENDPOINT OF PFS</p></li><li><p>INCYTE - PLANS TO FILE SBLA FOR TAFASITAMAB IN 2026</p></li><li><p>INCYTE - TRIAL MEETS SECONDARY ENDPOINT OF EVENT-FREE SURVIVAL</p></li><li><p>INCYTE: EXPECTS TO FILE A SBLA FOR TAFASITAMAB FOR FIRST-LINE TREATMENT OF ADULTS WITH NEWLY DIAGNOSED DLBCL IN H1 2026</p></li></ul><p>Source text: <span>ID:nBw35KXBqa</span></p><p>Further company coverage: <span>INCY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Incyte Announces Positive Topline Results From Study Of Tafasitamab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Incyte Announces Positive Topline Results From Study Of Tafasitamab\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-05 22:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Incyte Announces Positive Topline Results From Study Of Tafasitamab </title></head><body><p><span>Jan 5 (Reuters)</span><span> - </span>Incyte Corp <span>INCY.O</span>:</p><ul><li><p>INCYTE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL STUDY OF TAFASITAMAB (MONJUVI®/MINJUVI®) AS A FIRST-LINE TREATMENT FOR DIFFUSE LARGE B-CELL LYMPHOMA</p></li><li><p>INCYTE - PHASE 3 FRONTMIND TRIAL MEETS PRIMARY ENDPOINT OF PFS</p></li><li><p>INCYTE - PLANS TO FILE SBLA FOR TAFASITAMAB IN 2026</p></li><li><p>INCYTE - TRIAL MEETS SECONDARY ENDPOINT OF EVENT-FREE SURVIVAL</p></li><li><p>INCYTE: EXPECTS TO FILE A SBLA FOR TAFASITAMAB FOR FIRST-LINE TREATMENT OF ADULTS WITH NEWLY DIAGNOSED DLBCL IN H1 2026</p></li></ul><p>Source text: <span>ID:nBw35KXBqa</span></p><p>Further company coverage: <span>INCY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA8PF5XJ:1","article_id":"2601882274","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601882274","pubTimestamp":1767622528,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Incyte Announces Positive Topline Results From Study Of Tafasitamab Jan 5 (Reuters) - Incyte Corp INCY.O:INCYTE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL STUDY OF TAFASITAMAB (MONJUVI/MINJ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4139":"生物科技","INCY":"因塞特医疗","BK4585":"ETF&股票定投概念","BK4550":"红杉资本持仓","BK4588":"碎股"},"translate_title":"简介-Incyte宣布Tafasitamab研究的积极顶线结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9},"content_text":"BRIEF-Incyte Announces Positive Topline Results From Study Of Tafasitamab Jan 5 (Reuters) - Incyte Corp INCY.O:INCYTE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL STUDY OF TAFASITAMAB (MONJUVI®/MINJUVI®) AS A FIRST-LINE TREATMENT FOR DIFFUSE LARGE B-CELL LYMPHOMAINCYTE - PHASE 3 FRONTMIND TRIAL MEETS PRIMARY ENDPOINT OF PFSINCYTE - PLANS TO FILE SBLA FOR TAFASITAMAB IN 2026INCYTE - TRIAL MEETS SECONDARY ENDPOINT OF EVENT-FREE SURVIVALINCYTE: EXPECTS TO FILE A SBLA FOR TAFASITAMAB FOR FIRST-LINE TREATMENT OF ADULTS WITH NEWLY DIAGNOSED DLBCL IN H1 2026Source text: ID:nBw35KXBqaFurther company coverage: INCY.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601882274","isCrawlerRequest":true}